Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:enrollment |
6621
|
| gptkbp:focusesOn |
multi-cancer early detection
|
| gptkbp:foundIn |
low false positive rate
test can predict cancer signal origin with high accuracy multi-cancer early detection test can identify cancer signals in blood |
| gptkbp:goal |
evaluate performance of multi-cancer early detection test
|
| https://www.w3.org/2000/01/rdf-schema#label |
PATHFINDER study
|
| gptkbp:period |
interventional
|
| gptkbp:population |
asymptomatic adults
|
| gptkbp:principalInvestigator |
Deb Schrag
|
| gptkbp:publishedIn |
gptkb:Annals_of_Oncology
|
| gptkbp:recognizedBy |
NCT04241796
|
| gptkbp:result |
safety and performance of Galleri test
|
| gptkbp:resultsPublished |
2022
|
| gptkbp:sponsor |
GRAIL, Inc.
|
| gptkbp:startDate |
2019
|
| gptkbp:status |
completed
|
| gptkbp:uses |
Galleri blood test
|
| gptkbp:bfsParent |
gptkb:Galleri_multi-cancer_early_detection_test
|
| gptkbp:bfsLayer |
7
|